JCIA
RXRX icon

Jackson Creek Investment Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

Jackson Creek Investment Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-77,011
Closed -$594K – 363
2022
Q4 		$594K Buy
+77,011
New +$755K 0.26% 205

Other funds holding RXRX

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DCI
Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Jackson Creek Investment Advisors's RXRX Position: Q1 2023 in Review

Jackson Creek Investment Advisors sold out of Recursion Pharmaceuticals (RXRX) in Q1 2023, closing a stake of 77,011 shares — an estimated $594K sold.

Jackson Creek Investment Advisors first reported a position in RXRX in Q4 2022 and held it in 1 quarter. The position peaked at $594K in Q4 2022. 158 funds tracked by Wall St. Rank hold RXRX as of Q1 2023.

  • Jackson Creek Investment Advisors reported no remaining Recursion Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Jackson Creek Investment Advisors sold 77,011 Recursion Pharmaceuticals shares in Q1 2023, an estimated $594K.
  • Jackson Creek Investment Advisors first reported a position in Recursion Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • Jackson Creek Investment Advisors's Recursion Pharmaceuticals position peaked at $594K in Q4 2022.
  • 158 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2023.

Based on Jackson Creek Investment Advisors's 13F filing for Q1 2023, filed 2 May 2023.